TULVEGIO RIVOCERANIB
Live / Applied — First extension granted (statement of use) (as of 09 Feb 2026)
What this means for you
Not registered yet, but its 13 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98695795
- Mark type
- Design + words
- Filed
- 13 Aug 2024
- Published for opposition
- 08 Jul 2025
- Attorney of record
- Cynthia Johnson Walden
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances containing rivoceranib for the treatment of cancer
- Class 042 — Scientific and technological services: Development of therapeutics in the nature of pharmaceutical preparations for the treatment of cancer containing rivoceranib
Owner
- Elevar Therapeutics, Inc., Fort Lee, NJ, US
- Elevar Therapeutics, Inc., Salt Lake City, UT, US
Prosecution history
- 09 Feb 2026 — SOU EXTENSION 1 GRANTED
- 09 Feb 2026 — SOU EXTENSION 1 FILED
- 09 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Jul 2025 — PUBLISHED FOR OPPOSITION
- 02 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 08 May 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 05 Mar 2025 — NOTIFICATION OF PRIORITY ACTION E-MAILED
- 05 Mar 2025 — PRIORITY ACTION E-MAILED
- 05 Mar 2025 — PRIORITY ACTION WRITTEN
- 26 Feb 2025 — ASSIGNED TO EXAMINER